Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Johnson & Johnson to discontinue HIV vaccine study

by Gina Vitale
January 29, 2023 | A version of this story appeared in Volume 101, Issue 4

 

Johnson & Johnson is discontinuing its phase 3 Mosaico study for a vaccine regimen to prevent HIV infection. The regimen did not effectively prevent infection compared with a placebo, the study’s data and safety monitoring board concluded. “We remain steadfast in our commitment to advancing innovation in HIV, and we hope the data from Mosaico will provide insights for future efforts to develop a safe and effective vaccine,” said Penny Heaton, global therapeutic area head for vaccines at Janssen Research & Development, in a press release.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.